In today’s recent session, 1.37 million shares of the Kura Oncology Inc (NASDAQ:KURA) have been traded, and its beta is 0.53. Most recently the company’s share price was $5.88, and it changed around $0.03 or 0.51% from the last close, which brings the market valuation of the company to $474.97M. KURA at last check was trading at a discount to its 52-week high of $23.48, offering almost -299.32% off that amount. The share price’s 52-week low was $5.41, which indicates that the recent value has risen by an impressive 7.99% since then. We note from Kura Oncology Inc’s average daily trading volume that its 10-day average is 1.75 million shares, with the 3-month average coming to 1.51 million.
Kura Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended KURA as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Kura Oncology Inc is expected to report earnings per share of -0.6 for the current quarter.
Kura Oncology Inc (NASDAQ:KURA) trade information
Instantly KURA has been showing a green trend so far today with a performance of 0.51% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.14 on recent trading dayincreased the stock’s daily price by 4.23%. The company’s shares are currently down -32.49% year-to-date, but still up 4.63% over the last five days. On the other hand, Kura Oncology Inc (NASDAQ:KURA) is -19.34% down in the 30-day period. We can see from the shorts that 8.8 million shares have been sold at a short interest cover period of 7.25 day(s).
The consensus price target as assigned by Wall Street analysts is $12.5, which translates to bulls needing to increase their stock price by 52.96% from its current value. Analyst projections state that KURA is forecast to be at a low of $11 and a high of $14.
Kura Oncology Inc (KURA) estimates and forecasts
The year-over-year growth rate is expected to be 146.54%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 39.08M in revenue for the current quarter. 12 analysts expect Kura Oncology Inc to make 22.98M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -6.05%. Kura Oncology Inc earnings are expected to increase by 10.01% in 2025, but the outlook is positive 6.26% per year for the next five years.
KURA Dividends
Kura Oncology Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Kura Oncology Inc (NASDAQ:KURA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.15% of Kura Oncology Inc shares, and 102.24% of them are in the hands of institutional investors. The stock currently has a share float of 103.42%. Kura Oncology Inc stock is held by 258.0 institutions, with SUVRETTA CAPITAL MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 8.1602% of the shares, which is about 7.07 million shares worth $145.56 million.
BLACKROCK INC., with 8.0404% or 6.97 million shares worth $143.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.75 shares worth $16.22 million, making up 3.41% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.87 shares worth around $11.02 million, which represents about 2.32% of the total shares outstanding.
